Conservative treatment: Receive no antipaletet drug treatment and surgery
Antipaletet drug: Use of antipaletet drugs.
Patent Foramen Ovale Closure: Receive the surgery of Patent Foramen Ovale
Study summary
To establish a headache center in China that combines clinical, imaging and laboratory examinations, explore the feasible treatment options for migraine combined with patent foramen ovale, and search for the possible influencing factors, construct models that influence prognosis.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Meet the diagnostic criteria for migraine in the International Classification of Headache (ICHD-3);
* Confirmation of patent foramen ovale through transthoracic echocardiography(TTE) or transesophageal echocardiography(TEE)/right heart contrast echocardiography
* Agree to participate in the study and sign the informed consent form.
Exclusion Criteria:
* Can not sign the informed consent form or cooperate with follow-up.
Primary outcome measure(s)
The changes of migraine attacks — 3 months, 6 months, 1 year, 2 years and 3 years Migraine attacks are an important indicator of improvement in symptoms. The comparison measures included headache frequency, duration, pain degree, VAS scores, HIT-6 scores, HAMA, HAMD, and PSQI.
Trial sites (1)
Facility
City
Region
Status
Peking University Third Hospital
Beijing
China
Recruiting
More Peking University Third Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.